Fusion Pharmaceuticals Net Income

The latest net income for FUSN is $-100M as of March 2024. That compares with $-92M in the prior-year period — down 13.4% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Fusion Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, FUSN's net income moved from $-92M to $-100M — a 13.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fusion Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, FUSN currently prints $-100M for net income, while the sector average sits near $16B. That is roughly 100.6% below the sector mean. Large gaps often invite a closer look at Fusion Pharmaceuticals's growth, margins, and balance sheet.

A net income figure of $-100M for FUSN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting FUSN's net income ($-100M), review year-over-year change from $-92M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.